Clinical Research (03)

临床研究项目 项目摘要 维克森林浸信会综合癌症临床研究计划的主要目标 中心（WFBCCC）是作为一个假设驱动的孵化器和催化剂的临床翻译小说 治疗、诊断和支持性护理策略。CRP的目标将通过以下方式实现： 具体目标如下：（1）从世界癌症联合会的基本观点出发， 科学和人口科学计划与相关的生物标志物的新的治疗策略， （2）促进罕见或难以治疗的创新临床试验的开发和实施 癌症和转移部位;以及（3）加强对癌症相关症状科学的了解，包括 利用维克森林国家癌症研究所社区肿瘤学项目研究基地（WF NCORP RB; PI：Glenn Lesser，医学博士）。CRP研究由这些目标中的两个主题组成： 实验性疗法和解决健康差距，特别关注高发病率的癌症 在WFBCCC集水区。CRP由医学博士威廉·布莱克斯托克领导，Lesser博士被任命为 2015年8月任项目负责人。该方案有来自17个不同部门的43名成员。程序 成员有450万美元的同行评审校外资金（不包括培训赠款），其中58.7%来自 NCI。在成员的513份出版物中，23%是方案内出版物，14%是方案间出版物， 在2010年11月1日至2015年10月31日报告期内，63%是机构间的。CRP受益于 使用WF NCORP RB网络作为基于社区的临床试验平台的能力;反过来，WF NCORP RB可以翻译CRP的临床医生-科学家的专业知识，加强每个NCI- 支持实体。12个疾病导向小组（DOT）已在WFBCCC内正式成立 研究基础设施，以进一步加强WFBCCC科学的翻译。每个DOT都有一个特定的重点： 脑、乳腺、老年病、胃肠道、泌尿生殖系统、妇科、头颈部、血液学、肺， 黑色素瘤，儿科，肉瘤DOT由基础科学家、人口科学家和 临床医生，并作为强大的跨计划互动的工具，导致更多的创新和 全面的研究组合。在数据表3报告期间（2014年7月1日至2015年6月30日），268项试验 开放，累计2，875例患者。63%的试验是治疗试验，15%是 非治疗干预，21%为非干预性研究。12%的治疗试验 是导弹发射的

CLINICAL RESEARCH PROGRAM Project Summary The major goal of the Clinical Research Program (CRP) of the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) is to serve as a hypothesis-driven incubator and catalyst for the clinical translation of novel therapeutic, diagnostic, and supportive care strategies. The goal of the CRP will be achieved through the following Specific Aims: (1) Translate advances in the understanding of cancer from the WFBCCC's basic sciences and population science Programs into novel therapeutic strategies with correlative biomarkers of response; (2) Promote the development and conduct of innovative clinical trials for rare or difficult to treat cancers and sites of metastasis; and (3) Enhance understanding in cancer-related symptom science, including leveraging the Wake Forest National Cancer Institute Community Oncology Program Research Base (WF NCORP RB; PI: Glenn Lesser, M.D.). CRP research is comprised of two themes within these aims: experimental therapeutics and addressing health disparities, with particular focus on cancers of high incidence in the WFBCCC catchment area. CRP is led by William Blackstock, M.D., with Dr. Lesser appointed as Program Co-Leader in August of 2015. The Program has 43 members from 17 different departments. Program members have $4.5M in peer-reviewed extramural funding (excluding training grants) of which 58.7% is from the NCI. Among the members' 513 publications, 23% were intra-programmatic, 14% were inter-programmatic, and 63% were inter-institutional during the 11/01/10 – 10/31/15 reporting period. The CRP has benefited from the ability to use the WF NCORP RB network as a platform for community-based clinical trials; in turn, the WF NCORP RB can translate the expertise of the CRP's clinician-scientists, strengthening each of these NCI- supported entities. Twelve Disease-Oriented Teams (DOTs) have been formalized within the WFBCCC research infrastructure to further enhance translation of WFBCCC science. Each DOT has a specific focus: brain, breast, geriatrics, gastrointestinal, genitourinary, gynecologic, head and neck, hematologic, lung, melanoma, pediatrics, and sarcoma. DOTs are comprised of basic scientists, population scientists, and clinicians, and serve as vehicles for robust interprogrammatic interactions leading to more innovative and comprehensive research portfolios. During the Data Table 3 reporting period of 07/01/14-06/30/15, 268 trials were open and 2,875 patients were accrued. Sixty-three percent of the trials were treatment trials, 15% were non-treatment interventions, and 21% were non-interventional studies. Twelve percent of treatment trials were investigator-initiated.